nanoparticle-conjugated PvCSP subdomain vaccine

The nanoparticle-conjugated PvCSP subdomain vaccine is an experimental pre-erythrocytic malaria vaccine candidate designed to protect against *Plasmodium vivax* infection [8083]. Developed by researchers at the University of South Florida and Johns Hopkins University, the vaccine consists of recombinant *P. vivax* circumsporozoite protein (PvCSP) subdomains—specifically targeting the conserved flanking N- and C-terminal domains—surface-conjugated to biodegradable poly(lactic-co-glycolic acid) (PLGA) nanoparticles [8083]. It is formulated with the Toll-like receptor 9 (TLR9) agonist adjuvant CpG-1018 [8083]. By focusing on the conserved terminal regions of PvCSP rather than the highly variable central repeat region (which differs between the VK210 and VK247 strains), the vaccine aims to elicit broadly neutralizing, strain-transcending antibodies that inhibit sporozoite motility, cell traversal, and hepatocyte invasion [8083].

Other names

PLGA nanoparticle-conjugated PvCSP subdomain vaccinePLGA nanoparticle-conjugated rPvCSP subdomain vaccinenanoparticle-conjugated Plasmodium vivax circumsporozoite protein subdomain vaccinenanoparticle-conjugated rPvCSP subdomain vaccine